Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Oncology Frontrunne | Geron's Rytelo shows promise in MDS and MF treatment, with consistent efficacy across patient groups and a favorable safety profile |
Market Challenges | Despite Q1 sales shortfall, Geron sees renewed growth. Analysts project profitability by 2H 2025, but inventory issues and competition pose risks |
Expansion Potential | EU approval could boost Geron's global presence. Label expansion for Imetelstat, particularly in myelofibrosis, presents significant growth opportunities |
Analyst Outlook | Price targets range from $4 to $9, reflecting varied perspectives on Geron's future. The company's path to profitability remains a key focus for investors |
Metrics to compare | GERN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGERNPeersSector | |
---|---|---|---|---|
P/E Ratio | −10.6x | −0.4x | −0.5x | |
PEG Ratio | −0.16 | −0.01 | 0.00 | |
Price/Book | 3.6x | 1.2x | 2.6x | |
Price / LTM Sales | 5.7x | 4.5x | 3.3x | |
Upside (Analyst Target) | 181.7% | 292.2% | 38.7% | |
Fair Value Upside | Unlock | 27.7% | 5.0% | Unlock |